(A) Protein expression of the Bcl-2 family was examined by western blotting. (B) Cells were treated with cisplatin (4.5 µg/ml) for 24 h, and the mRNA expression of Bcl-xL and survivin was examined by qPCR. (C) Cells were transfected with control, Bcl-xL, or survivin siRNA, and the protein expression was examined by western blotting. (D & E) Cells were transfected with control, Bcl-xL, or survivin siRNA, and cell viability and apoptosis was analyzed by MTT assay and PI staining. Each experiment was done in triplicate. Results are expressed as mean ± SEM. *, p<0.05 as compared with MG-63/vector group; #
P<0.05 compared with MG-63/CCN2 cisplatin-treated control group.